Clearing a Path in Chronic Rhinosinusitis With Nasal Polyps
Closing Gaps in Diagnosis and Treatment
The Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps
Bachert C. J Allergy Clin Immunol Pract. 2021;9(3):1099-1106
Biomarkers in chronic rhinosinusitis with nasal polyps.
Workman AD, et al. Immunol Allergy Clin North Am. 2018; 38(4):679-692.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, et al. Lancet. 2019;394(10209):1638-1650.
Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy.
Albrecht T, et al. World Allergy Organ J. 2023;16(5):100780
The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP.
Campion NJ, et al. J Otolaryngol Head Neck Surg. 2023;52(1):56
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, et al. J Allergy Clin Immunol. 2020;146(3):595-605.
EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial.
Gomez LDP, et al. J Allergy Clin Immunol. 2022;149(2): Abstract 145.
AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps.
Siddiqui S, et al. ERJ Open Research. 2022;8(4): 00085-2022
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomized, double-blind, placebo-controlled, phase 3 trial.
Han JK, et al. Lancet Respir Med. 2021;9(10):1141-1153.
Real-Life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps.
Dominguez-Sosa MS, et al. Biomedicines. 2023;11(2):485
Mepolizumab induced loss of smell improvement in patients with chronic rhinosinusitis with nasal polyps from the SYNAPSE Study.
Mullo J, et al. J Allergy Clin Immunol. 2022;149(2): Abstract 481.
Clinical Practice Guidelines and Position Papers
EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP
Fokkens WJ, et al. Rhinology. 2024. Online ahead of print.
Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics.
De Corso E, et al. Acta Otorhinolaryngol Ital. 2023;43(suppl 1):S3-S13.
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management.
Bachert C, et al. J Allergy Clin Immunol. 2021;147(1):29-36.
International consensus statement on allergy and rhinology: rhinosinusitis 2021.
Orlandi RR, et al. Int Forum Allergy Rhinol. 2021;11(3):213–739
European position paper on rhinosinusitis and nasal polyps, 2020.
Fokkens WJ, et al. Rhinology. 2020;58(suppl S29):1-464.
Clinical Practice Tools
Sino-Nasal Outcome Test (SNOT-22) Questionnaire
Sinus Control Test (SCT)
Questionnaire of Olfactory Disorders (QOD)
Patient Advocacy Organizations and Resources
Asthma and Allergy Foundation of America (AAFA)
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases including nasal polyps through education, advocacy, and research.
American Academy of Allergy, Asthma & Immunology (AAAAI)
AAAAI is dedicated to the advancement of the knowledge and practice of allergy, asthma, and immunology for optimal patient care.
Clearing a Path in Chronic Rhinosinusitis With Nasal Polyps
Closing Gaps in Diagnosis and Treatment
| Faculty: | Joseph K. Han, MD, FARS, FAAOA; Flavia Hoyte, MD |
| Release: | 03/08/2024 |
| Expiration: | 03/08/2025 |
